Product category |
|
Therapeutic indication |
|
Dosing |
- For ages 6 months to <3 years – 1 x 100 mg, 3 to 6 years - 2 x 100 mg
- Administration should be followed immediately by referral to health facility able to administer parenteral treatment
|
Efficacy |
- Halves death and disability in the target population
- Implementation programme in Zambia supported by MMV resulted in >95% reduction in the severe malaria case fatality rate
|
Key features |
|
Challenges |
- Requires close supervision and referral mechanisms to ensure correct use; risk of monotherapy if not followed up with injectable artesunate and ACT
|
Status |
- 100 mg artesunate rectal capsules included in WHO Essential Medicines List (April 2017 revision)
- 7.6 million artesunate rectal capsules have been supplied since 2017**
- Product registered in 9 malaria-endemic countries
|
Next milestone |
|
Previously |
|
MMV Project Director |
|